NOVARTIS AG-REG

Novartis’ del‑brax breakthrough in FSHD could reshape the rare‑disease market, offering first‑in‑class therapy and high value to payers while boosting Swiss equity momentum.

Novartis shares fell amid a broader Swiss healthcare dip, showing that even strong pipelines can struggle when macro‑economics, pricing and competition weigh heavily.

Novartis’s new radioligand therapy Pluvicto shows promise yet faces regulatory, cost, and competitive hurdles—analyzing its oncology and immunology pipeline for investors.